$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

$csbr Overview Financials Valuation SEC Filings Company Website

2015 Form 10-K Financial Statement

#000114420415044834 Filed on July 29, 2015

Income Statement

Concept	2015	2014 Q2	2014
Revenue	$8.863M	$2.460M	$11.55M
YoY Change	-23.26%	33.7%	38.77%
Cost Of Revenue	$7.630M	$950.0K	$3.600M
YoY Change	111.94%	-39.1%	-32.46%
Gross Profit	$1.230M	$1.510M	$7.950M
YoY Change	-84.53%	439.29%	165.0%
Gross Profit Margin	13.88%	61.38%	68.83%
Selling, General & Admin	$9.623M	$3.240M	$9.282M
YoY Change	3.67%	83.05%	27.22%
% of Gross Profit	782.36%	214.57%	116.75%
Research & Development	$4.845M	$650.0K	$2.265M
YoY Change	113.91%	27.45%	17.97%
% of Gross Profit	393.9%	43.05%	28.49%
Depreciation & Amortization	$214.0K	$50.00K	$213.0K
YoY Change	0.47%	0.0%	4.93%
% of Gross Profit	17.4%	3.31%	2.68%
Operating Expenses	$22.10M	$3.890M	$17.81M
YoY Change	24.09%	71.37%	22.46%
Operating Profit	-$13.24M	-$2.380M	-$6.260M
YoY Change	111.47%	19.6%	0.63%
Interest Expense	$400.0K	$240.0K	-$970.0K
YoY Change	-141.24%	-580.0%	1285.71%
% of Operating Profit
Other Income/Expense, Net	$225.0K	-$130.0K	-$1.129M
YoY Change	-119.93%		1040.4%
Pretax Income	-$13.01M	-$2.270M	-$7.389M
YoY Change	76.11%	11.27%	16.91%
Income Tax	$127.0K	$0.00	$17.00K
% Of Pretax Income
Net Earnings	-$13.14M	-$2.270M	-$7.406M
YoY Change	77.42%	10.73%	17.0%
Net Earnings / Revenue	-148.26%	-92.28%	-64.12%
Basic Earnings Per Share	-$2.20		-$0.11
Diluted Earnings Per Share	-$2.20	-$407.5K	-$0.11
COMMON SHARES
Basic Shares Outstanding	5.985M shares	66.89M shares	66.86M shares
Diluted Shares Outstanding	6.424M shares		66.86M shares

Balance Sheet

Concept	2015	2014 Q2	2014
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.360M	$5.890M	$5.890M
YoY Change	58.91%	-38.39%	-38.39%
Cash & Equivalents	$9.360M	$5.891M	$5.890M
Short-Term Investments
Other Short-Term Assets	$350.0K	$380.0K	$380.0K
YoY Change	-7.89%	18.75%	18.75%
Inventory
Prepaid Expenses
Receivables	$1.060M	$1.325M	$1.330M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$10.76M	$7.599M	$7.600M
YoY Change	41.58%	-26.76%	-26.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$450.0K	$434.0K	$430.0K
YoY Change	4.65%	4.83%	4.88%
Goodwill		$669.0K
YoY Change		0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$160.0K	$170.0K	$170.0K
YoY Change	-5.88%	-10.53%	-10.53%
Total Long-Term Assets	$1.290M	$1.268M	$1.270M
YoY Change	1.57%	-0.55%	0.0%
TOTAL ASSETS
Total Short-Term Assets	$10.76M	$7.599M	$7.600M
Total Long-Term Assets	$1.290M	$1.268M	$1.270M
Total Assets	$12.05M	$8.867M	$8.870M
YoY Change	35.85%	-23.89%	-23.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.410M	$981.0K	$980.0K
YoY Change	43.88%	-18.52%	-18.33%
Accrued Expenses	$370.0K	$587.0K	$590.0K
YoY Change	-37.29%	-3.93%	-3.28%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.800M	$3.659M	$3.660M
YoY Change	3.83%	24.92%	24.91%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$190.0K	$0.00	$2.010M
YoY Change	-90.55%	-100.0%	91.43%
Total Long-Term Liabilities	$190.0K	$0.00	$2.010M
YoY Change	-90.55%	-100.0%	91.43%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.800M	$3.659M	$3.660M
Total Long-Term Liabilities	$190.0K	$0.00	$2.010M
Total Liabilities	$3.990M	$5.670M	$5.670M
YoY Change	-29.63%	42.64%	42.46%
SHAREHOLDERS EQUITY
Retained Earnings		-$38.88M
YoY Change		23.53%
Common Stock		$43.33M
YoY Change		83.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$1.252M
YoY Change		0.0%
Treasury Stock Shares		3.236M shares
Shareholders Equity	$8.060M	$3.197M	$3.200M
YoY Change
Total Liabilities & Shareholders Equity	$12.05M	$8.867M	$8.870M
YoY Change	35.85%	-23.89%	-23.86%

Cashflow Statement

Concept	2015	2014 Q2	2014
OPERATING ACTIVITIES
Net Income	-$13.14M	-$2.270M	-$7.406M
YoY Change	77.42%	10.73%	17.0%
Depreciation, Depletion And Amortization	$214.0K	$50.00K	$213.0K
YoY Change	0.47%	0.0%	4.93%
Cash From Operating Activities	-$9.630M	$130.0K	-$3.430M
YoY Change	180.76%	-111.21%	-20.08%
INVESTING ACTIVITIES
Capital Expenditures	$119.0K	-$70.00K	$234.0K
YoY Change	-49.15%	250.0%	310.53%
Acquisitions
YoY Change
Other Investing Activities	$10.00K
YoY Change
Cash From Investing Activities	-$114.0K	-$70.00K	-$230.0K
YoY Change	-50.43%	250.0%	303.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$13.21M	20.00K	20.00K
YoY Change	65950.0%	-133.33%	-99.78%
NET CHANGE
Cash From Operating Activities	-$9.630M	130.0K	-3.430M
Cash From Investing Activities	-$114.0K	-70.00K	-230.0K
Cash From Financing Activities	$13.21M	20.00K	20.00K
Net Change In Cash	$3.466M	80.00K	-3.640M
YoY Change	-195.22%	-106.45%	-175.96%
FREE CASH FLOW
Cash From Operating Activities	-$9.630M	$130.0K	-$3.430M
Capital Expenditures	$119.0K	-$70.00K	$234.0K
Free Cash Flow	-$9.749M	$200.0K	-$3.664M
YoY Change	166.08%	-117.54%	-15.75%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-24000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3433000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-9630000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	234000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	119000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-234000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-114000	USD
CY2014	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2015	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	11220000	USD
CY2014	csbr	Proceeds From Exercise Of Options And Warrants ProceedsFromExerciseOfOptionsAndWarrants	21000	USD
CY2015	csbr	Proceeds From Exercise Of Options And Warrants ProceedsFromExerciseOfOptionsAndWarrants	2000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	21000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	13210000	USD
CY2015Q2	us-gaap	Liabilities Liabilities	3988000	USD
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	70000	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	108000	USD
CY2014Q2	us-gaap	Treasury Stock Value TreasuryStockValue	1252000	USD
CY2014Q2	us-gaap	Goodwill Goodwill	669000	USD
CY2015Q2	us-gaap	Goodwill Goodwill	669000	USD
CY2014Q2	us-gaap	Assets Assets	8867000	USD
CY2014Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2011000	USD
CY2015Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2014Q2	us-gaap	Liabilities Liabilities	5670000	USD
CY2015Q2	us-gaap	Treasury Stock Value TreasuryStockValue	1252000	USD
CY2014Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	43259000	USD
CY2015Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	61223000	USD
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-38880000	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-52020000	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	3197000	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	8059000	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2807000	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3162000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-6260000	USD
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-164000	USD
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	66863915	shares
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	71824146	shares
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	2807000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	3162000	USD
CY2014	us-gaap	Depreciation And Amortization DepreciationAndAmortization	213000	USD
CY2015	us-gaap	Depreciation And Amortization DepreciationAndAmortization	214000	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	825000	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-265000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	68000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-37000	USD
CY2014	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-27000	USD
CY2015	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-2000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-223000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	433000	USD
CY2014	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-24000	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-232000	USD
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	977000	USD
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-82000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5891000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9357000	USD
CY2014Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1325000	USD
CY2015Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1060000	USD
CY2014Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	383000	USD
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	346000	USD
CY2014Q2	us-gaap	Assets Current AssetsCurrent	7599000	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	10763000	USD
CY2014Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	165000	USD
CY2015Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	163000	USD
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	434000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	452000	USD
CY2015Q2	us-gaap	Assets Assets	12047000	USD
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	981000	USD
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1414000	USD
CY2014Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	587000	USD
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	373000	USD
CY2014Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2091000	USD
CY2015Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2009000	USD
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3659000	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3796000	USD
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1129000	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	225000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7389000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13013000	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17000	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	127000	USD
CY2014	csbr	Translational Oncology Solutions TranslationalOncologySolutions	9286000	USD
CY2014	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	11550000	USD
CY2015	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	8863000	USD
CY2014	csbr	Cost Of Personalized Oncology Solutions CostOfPersonalizedOncologySolutions	2731000	USD
CY2015	csbr	Cost Of Personalized Oncology Solutions CostOfPersonalizedOncologySolutions	2733000	USD
CY2014	csbr	Cost Of Translational Oncology Solutions CostOfTranslationalOncologySolutions	3532000	USD
CY2015	csbr	Cost Of Translational Oncology Solutions CostOfTranslationalOncologySolutions	4900000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2265000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4845000	USD
CY2014	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3155000	USD
CY2015	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4283000	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6127000	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5340000	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	17810000	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	22101000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-13238000	USD
CY2014	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-965000	USD
CY2015	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	981000	USD
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-170000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-7406000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-13140000	USD
CY2015	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3670000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3466000	USD
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	26627704	shares
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9561000	USD
CY2015Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	70000	USD
CY2015Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	685000	USD
CY2015Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	493000	USD
CY2015Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1250000	USD
CY2015Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	798000	USD
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	49366102	shares
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.021	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.026	pure
CY2014	csbr	Effective Income Tax Rate Reconciliation Permanen Tdifferences EffectiveIncomeTaxRateReconciliationPermanenTdifferences	-0.056	pure
CY2015	csbr	Effective Income Tax Rate Reconciliation Permanen Tdifferences EffectiveIncomeTaxRateReconciliationPermanenTdifferences	0.009	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.021	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.069	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.272	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.308	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.014	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0	pure
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002	pure
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.011	pure
CY2014Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	38000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	21000	USD
CY2014Q2	csbr	Deferred Tax Assets Deferred Expense Depreciation And Amortization DeferredTaxAssetsDeferredExpenseDepreciationAndAmortization	9000	USD
CY2015Q2	csbr	Deferred Tax Assets Deferred Expense Depreciation And Amortization DeferredTaxAssetsDeferredExpenseDepreciationAndAmortization	0	USD
CY2014Q2	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	1000	USD
CY2015Q2	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	1000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4511000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4803000	USD
CY2014Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	556000	USD
CY2015Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	433000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	244000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	235000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5608000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9719000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10968000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	15212000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10968000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15212000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	0	USD
CY2015Q2	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	0	USD
CY2015	dei	Document Type DocumentType	10-K
CY2015	dei	Amendment Flag AmendmentFlag	false
CY2015	dei	Document Period End Date DocumentPeriodEndDate	2015-04-30
CY2015	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2015	dei	Entity Registrant Name EntityRegistrantName	CHAMPIONS ONCOLOGY, INC.
CY2015	dei	Entity Central Index Key EntityCentralIndexKey	0000771856
CY2015	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--04-30
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2014Q4	dei	Entity Public Float EntityPublicFloat	30000000	USD
CY2015	dei	Trading Symbol TradingSymbol	CSBR
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	104425102	shares
CY2014Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2015Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	192000	USD
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i>Use of Estimates</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 9pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
CY2014	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	100000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13140000	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7306000	USD
CY2015	us-gaap	Revenue Recognition Deferred Revenue RevenueRecognitionDeferredRevenue	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i>Deferred Revenue</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 9pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Deferred revenue represents payments received in advance for products to be delivered.  When products are delivered, deferred revenue is then recognized as earned.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-124000	USD
CY2015	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	USD
CY2014Q2	csbr	Estimated Fair Value Of Warrants EstimatedFairValueOfWarrants	2000000	USD
CY2015Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2000	USD
CY2015Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	636000	USD
CY2014Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	884000	USD
CY2014Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2000	USD
CY2015Q2	us-gaap	Deferred Revenue DeferredRevenue	258000	USD
CY2015	us-gaap	Deferred Revenue Revenue Recognized DeferredRevenueRevenueRecognized	724000	USD
CY2014	us-gaap	Deferred Revenue Revenue Recognized DeferredRevenueRevenueRecognized	194000	USD
CY2015	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3000	USD
CY2015	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	124000	USD
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	127000	USD
CY2015	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-25948000	USD
CY2015	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1771000	USD
CY2015	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	8000	USD
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-27711000	USD
CY2015	csbr	Federal Income Tax Valuation Allowance FederalIncomeTaxValuationAllowance	25948000	USD
CY2015	csbr	State And Local Income Tax Valuation Allowance StateAndLocalIncomeTaxValuationAllowance	1771000	USD
CY2015	csbr	Foreign Income Tax Valuation Allowance ForeignIncomeTaxValuationAllowance	-8000	USD
CY2015	us-gaap	Concentration Risk Percentage1 ConcentrationRiskPercentage1	0.10	pure
CY2015	csbr	Valuation Allowances ValuationAllowances	27711000	USD
CY2015	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0	USD
CY2015	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	3000	USD
CY2015	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	124000	USD
CY2014	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2014	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5000	USD
CY2014	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	12000	USD
CY2014	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	17000	USD
CY2014	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2015000	USD
CY2014	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-148000	USD
CY2014	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2163000	USD
CY2014	csbr	Federal Income Tax Valuation Allowance FederalIncomeTaxValuationAllowance	2015000	USD
CY2014	csbr	State And Local Income Tax Valuation Allowance StateAndLocalIncomeTaxValuationAllowance	148000	USD
CY2014	csbr	Foreign Income Tax Valuation Allowance ForeignIncomeTaxValuationAllowance	0	USD
CY2014	csbr	Valuation Allowances ValuationAllowances	2163000	USD
CY2014	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0	USD
CY2014	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	5000	USD
CY2014	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	12000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	192013000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	64149000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	0	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	256162000	USD
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	-9206000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2807000	USD
CY2014	csbr	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	21000	USD
CY2014	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2014	csbr	Amendment To Redeemable Stock Value AmendmentToRedeemableStockValue	16881000	USD
CY2014	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	100000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2948000	USD
CY2015	csbr	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	2000	USD
CY2014	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0	pure
CY2013Q1	csbr	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	9100000	USD
CY2013Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	500000	USD
CY2013Q1	csbr	Common Stock Purchase Price CommonStockPurchasePrice	0.50
CY2011Q1	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	12533333	shares
CY2011Q1	csbr	Common Stock Purchase Price CommonStockPurchasePrice	0.75
CY2011Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	9400000	USD
CY2011Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	500000	USD
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	107561338	shares
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70122086	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	104425102	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	66885850	shares
CY2015Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	3236236	shares
CY2014Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	3236236	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.008	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.007	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.019	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.024	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.86	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.84	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.02	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.02	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2013Q4	csbr	Stock Options Award Shares To Purchase Common Stock StockOptionsAwardSharesToPurchaseCommonStock	200000	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.61
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.96
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	15000	USD
CY2015Q2	csbr	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstanding	25318082	shares
CY2015	csbr	Warrant Modification Charge WarrantModificationCharge	586000	USD
CY2014	csbr	Warrant Modification Charge WarrantModificationCharge	0	USD
CY2015	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-5000	USD
CY2014	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2015	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	5000	USD
CY2014	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	USD
CY2015	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2000000	USD
CY2015	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	12000	USD
CY2015	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	11160000	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1616000	USD
CY2015	csbr	Adjustments To Additional Paid In Capital Stock Option Modification AdjustmentsToAdditionalPaidInCapitalStockOptionModification	214000	USD
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	23351037	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	21160562	shares
CY2015	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3750	shares
CY2015	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Canceled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod	19872875	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	151250	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	435704	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	24048020	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	24048020	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	17111080	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.01
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.66
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.49
CY2015	csbr	Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice	1.04
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.96
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.99
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.48
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.49
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y8M12D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y10M24D
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	985000	USD
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4166000	USD
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	4166000	USD
CY2015Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2879000	USD
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13890205	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	9793332	shares
CY2014	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	33750	shares
CY2014	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Canceled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod	0	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	72500	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	226250	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	23351037	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	13564577	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.85
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.23
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.63
CY2014	csbr	Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice	0
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.82
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.73
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.85
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y6M
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M6D
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	89000	USD
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	985000	USD
CY2014Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	927000	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	214000	USD
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	213000	USD
CY2014	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grant In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm	P7Y6M
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M
CY2015	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grant In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm	P6Y8M12D
CY2013Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	9300000	USD
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	0	USD
CY2013Q1	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	18600000	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2015	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	124000	USD
CY2014	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2014	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2014	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	0	USD
CY2015	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	2000000	USD
CY2014	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2015	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	880000	USD
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	71824146	shares
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	66863915	shares
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2015	us-gaap	Gain On Derivative Instruments Pretax GainOnDerivativeInstrumentsPretax	980519	USD
CY2014	us-gaap	Gain On Derivative Instruments Pretax GainOnDerivativeInstrumentsPretax	0	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-14120339	USD
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-7406367	USD
CY2015	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	5268777	shares
CY2014	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	77092923	shares
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	66863915	shares
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2015	csbr	Repurchase Of Stock In Put Option RepurchaseOfStockInPutOption	0.40
CY2015	csbr	Share Based Compensation Arrangement By Share Based Payment Award Shares Exchanged In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesExchangedInPeriod	19872875	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	17617929	shares
CY2015	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	213951	USD
CY2015	csbr	Additional Stock Option Plan Expense AdditionalStockOptionPlanExpense	386578	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12047000	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8867000	USD
CY2015	csbr	Stock Issued During Period Value Conversion Of Convertible Notes And Accrued Interest StockIssuedDuringPeriodValueConversionOfConvertibleNotesAndAccruedInterest	2060000	USD
CY2015	csbr	Reclassification Of Warrant Liability To Equity ReclassificationOfWarrantLiabilityToEquity	1616000	USD
CY2014	csbr	Reclassification Of Warrant Liability To Equity ReclassificationOfWarrantLiabilityToEquity	0	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Remainder Of Fiscal Year CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear	91000	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	-23000	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	114000	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	16000	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	23000	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	24000	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	25000	USD
CY2015Q2	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	26000	USD
CY2014	us-gaap	Concentration Risk Percentage1 ConcentrationRiskPercentage1	0.10	pure
CY2015	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0	pure
CY2014Q4	us-gaap	Capital Leases Future Minimum Payments Executory Costs CapitalLeasesFutureMinimumPaymentsExecutoryCosts	149000	USD
CY2015Q2	us-gaap	Capital Leases Of Lessee Contingent Rentals Basis Spread On Variable Rate CapitalLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate	0.05	pure
CY2015	us-gaap	Capital Leases Income Statement Amortization Expense CapitalLeasesIncomeStatementAmortizationExpense	12405	USD
CY2014Q4	csbr	Capital Leases Monthly Payments CapitalLeasesMonthlyPayments	3000	USD
CY2014Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2013Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2015Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	100000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	21000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2015Q2	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	100000	USD
CY2015	csbr	Issuance Cost Of Common Stock IssuanceCostOfCommonStock	880000	USD
CY2014	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
CY2015	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	100000	USD
CY2015Q1	csbr	Estimated Fair Value Of Warrants EstimatedFairValueOfWarrants	1600000	USD
CY2015	csbr	Effective Income Tax Rate Reconciliation Increase In Uncertain Tax Position EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition	-0.008	pure
CY2014	csbr	Effective Income Tax Rate Reconciliation Increase In Uncertain Tax Position EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition	0	pure
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	79000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD

Files In Submission

Name	View Source	Status
0001144204-15-044834-index-headers.html	Edgar Link	pending
0001144204-15-044834-index.html	Edgar Link	pending
0001144204-15-044834.txt	Edgar Link	pending
0001144204-15-044834-xbrl.zip	Edgar Link	pending
csbr-20150430.xml	Edgar Link	completed
csbr-20150430.xsd	Edgar Link	pending
csbr-20150430_cal.xml	Edgar Link	unprocessable
csbr-20150430_def.xml	Edgar Link	unprocessable
csbr-20150430_lab.xml	Edgar Link	unprocessable
csbr-20150430_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v415746_10k.htm	Edgar Link	pending
v415746_ex23-1.htm	Edgar Link	pending
v415746_ex23-2.htm	Edgar Link	pending
v415746_ex31-1.htm	Edgar Link	pending
v415746_ex31-2.htm	Edgar Link	pending
v415746_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

2015 Form 10-K Financial Statement

#000114420415044834 Filed on July 29, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR CHAMPIONS ONCOLOGY, INC. Stock $csbr

2015 Form 10-K Financial Statement

#000114420415044834 Filed on July 29, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr